drugset / Trial / NCT00866918

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

NCT00866918

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Timeline

Start
2009-03-09
Primary completion
2015-06-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule Intrathecal
Subject Idarubicin Small molecule Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule Oral
Subject Methotrexate Small molecule Oral
Subject Mitoxantrone Small molecule Intravenous
Subject Tretinoin Small molecule Oral
Subject arsenic trioxide Small molecule Intravenous